NCT06119685 2025-06-03IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersIndapta Therapeutics, INC.Phase 1/2 Recruiting128 enrolled
NCT04887259 2025-01-27Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AMLLava TherapeuticsPhase 1 Terminated16 enrolled